Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 121,433 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Tumor, Ovarian Cancer
Interventions: NKTR-102 q14d, NKTR-102 q21d; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 11
States / cities: Highland, California • Los Angeles, California • Newport Beach, California + 8 more

Conditions: Glaucoma
Interventions: Use of ologen Collagen Matrix in trabeculectomy (ologen), Use of Mitomycin-C (MMC) in trabeculectomy; Device · Drug
Lead sponsor: Aeon Astron Europe B.V.; Industry
Eligibility: 30 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: Rogers, Arkansas • Chicago, Illinois • Newark, New Jersey + 4 more

Conditions: Melanoma (Skin)
Interventions: Autologous dendritic cell-adenovirus CCL21 vaccine; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Schizophrenia
Interventions: SEP-363856; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Little Rock, Arkansas • Pico Rivera, California • San Diego, California + 3 more

Conditions: Arnica, Third Molar Extraction
Interventions: SinEcch, Placebo; Drug · Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tumors
Interventions: G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Aging, Older Adults, Healthy
Interventions: Intervention, Control; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 50 Years to 100 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Lancaster, California • Los Angeles, California • Montebello, California + 2 more

Conditions: Acute Gout
Interventions: Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 96
States / cities: Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more

Conditions: Heart Failure
Interventions: AZD4831 Oral Myeloperoxidase Inhibitor, Placebo oral capsule; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder, ADHD
Interventions: Cycling Exercise; Behavioral
Lead sponsor: Kent State University; Other
Eligibility: 18 Years to 26 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Kent, Ohio

Conditions: Healthy Volunteers
Interventions: E2511, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Aging, Pain
Interventions: RHA®4 with new anesthetic agent, RHA®4-Lidocaine; Device
Lead sponsor: Teoxane SA; Industry
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Beverly Hills, California • Coral Gables, Florida • Chicago, Illinois

Conditions: Pregnancy, Breastfeeding, Contraception, Cervical Cancer, Postpartum Depression
Interventions: Postpartum follow up appointment 2-3 weeks after delivery, Postpartum follow up 6-8wk after delivery; Other
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 344 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Food Sensitivities, Headache, Backache, Indigestion, Eczema, Acne, Hives and Itching of the Skin
Interventions: NAET Procedures; Procedure
Lead sponsor: Nambudripad's Allergy Research Foundation; Other
Eligibility: 2 Years to 78 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Buena Park, California

Conditions: Hemophilia A With Inhibitors
Interventions: activated prothrombin complex concentrate (FEIBA); Drug
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 24 Months and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Vitamin D Deficiency
Interventions: cholecalciferol; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 50 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mood Disorders, Depressive Disorders, Depression, Chronic Depression
Interventions: Bright light box, High-output negative ion generator, Low-output negative ion generator; Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: Middletown, Connecticut • New York, New York

Conditions: Non-Healing Ulcer of Skin, Autofluorescence Imaging
Interventions: MolecuLight; Device
Lead sponsor: Wound Care Plus, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Blue Springs, Missouri

Conditions: Psoriatic Arthritis
Interventions: Placebo, Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 59
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more

Conditions: Obesity, Diabetes, Nutrition, Physical Health
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 12 Years to 17 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Milwaukee and Madison, Wisconsin

Conditions: Healthy
Interventions: Quinine Sulfate Capsules 324 mg, Quinine Sulphate Tablets 300 mg; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Meloxicam Tablets 15 mg, Mobic® Tablets 15 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Depression, Anxiety Disorders
Interventions: SilverCloud; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

Efficacy of Arnica Montana in Reducing Postoperative Edema and Pain

A Phase I Study of G3139 Subcutaneous in Solid Tumors

Aging Mastery Program® (AMP) Evaluation

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)

Effects of Exercise Intensity on ADHD Symptoms

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

RHA® 4 With New Anesthetic - Nasolabial Folds

The Effect of Early Versus Traditional Follow-Up on Breastfeeding Rates at 6 Months

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

A Pilot Study of the Effect of Dietary Fat Type and Amount on Vitamin D3 Absorption

Clinical Trials of Two Non-drug Treatments for Chronic Depression

Retrospective Database Review at LTC and SNFs

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Effects of Environmental Opportunities and Barriers on Physical Activity, Fitness, and Health in Hispanic Children in Wisconsin

A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions

Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg

Toward Understanding Drivers of Patient Engagement With Digital Mental Health Interventions - Part II

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...